1: Spravato^® produktresumé.

2: Mattingly GW, Anderson RH. Intranasal esketamine. Current Psychiatry. 2019; 18(5): 31-38

3: Popova V, Daly E, Trivedi M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression:A randomized double-blind active controlled study. Am J Psychiatry 2019; 176(6): 428-438.

4: Daly E, Trivedi M, Janik A, et al. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial. JAMA Psychiatry. 2019 Jun 5. doi: 10.1001/jamapsychiatry.2019.1189. [Epub ahead of print] https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2735111

Spravato^® – Introduktion (Jesper Riise - Medical Advisor)